<DOC>
	<DOCNO>NCT00365378</DOCNO>
	<brief_summary>Subjects receive HPV 16 L1 VLP vaccine placebo ( 1:1 ratio ) . Endpoints include efficacy , immunogenicity , safety .</brief_summary>
	<brief_title>Study Human Papillomavirus ( HPV ) 16 Vaccine Prevention HPV 16 Infection 16- 23-Year-Old Females ( V501-005 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , unmarried female age 16 23 year intact uterus Not pregnant enrollment Agreed use effective contraception Month 7 study A lifetime history 0 5 male partner subject engage least one episode insertive intercourse No prior history Human Papillomavirus ( HPV ) vaccination No receipt vaccination within 1 month prior enrollment plan receive vaccination within 1 month prior dose study vaccine No prior history abnormal Papanicolaou ( Pap ) test show Squamous intraepithelial lesion ( SIL ) biopsy show Cervical intraepithelial neoplasia ( CIN )</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>